Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Intangibles (2013 - 2018)

ProQR Therapeutics recorded quarterly Intangibles of -$44514.5 in Q4 2018, down 98231.53% quarter-over-quarter from $45.36 in Q3 2018, and down 196.94% year-over-year from $45919.9 in Q4 2017.

ProQR Therapeutics' Intangibles history runs 6 years deep, the most recent figure standing at -$44514.5 for Q4 2018.

  • In Q4 2018, Intangibles fell 196.94% year-over-year to -$44514.5; the TTM figure through Dec 2018 stood at -$44514.5 (down 196.94% YoY), while the FY2018 annual figure was -$44514.5, down 196.94% from the prior year.
  • Intangibles came in at -$44514.5 for Q4 2018 at ProQR Therapeutics, down from $45.36 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $203722.9 in Q4 2014 to a low of -$44514.5 in Q4 2018.
  • A 5-year average of $66100.7 and a median of $46544.3 in 2018 frame the typical range for Intangibles.
  • Across the five-year window, Intangibles jumped 283.79% in 2014 and tumbled 196.94% in 2018, its largest moves.
  • ProQR Therapeutics' Intangibles stood at $203722.9 in 2014, then retreated by 24.14% to $154552.5 in 2015, then sank by 37.12% to $97175.2 in 2016, then tumbled by 52.75% to $45919.9 in 2017, then sank by 196.94% to -$44514.5 in 2018.
  • According to Business Quant data, Intangibles over the past three periods registered -$44514.5, $45.36, and $46544.3 for Q4 2018, Q3 2018, and Q2 2018 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 4.41 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 11,640.44
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 418.50 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.29 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 ProQR Therapeutics 174.11 Mn 66.54 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2018 -44,514.46
Sep 30, 2018 45.36
Jun 30, 2018 46,544.33
Mar 31, 2018 47.91
Dec 31, 2017 45,919.87
Dec 31, 2016 97,175.18
Sep 30, 2016 114.97
Dec 31, 2015 154,552.54
Mar 31, 2015 171,734.54
Dec 31, 2014 203,722.86
Sep 30, 2014 51,764.37
Dec 31, 2013 53,082.49